Ionis analyst coverage
Web12 apr. 2024 · Ionis Pharmaceuticals Stock Performance. IONS opened at $37.23 on Tuesday. Ionis Pharmaceuticals has a 12-month low of $31.46 and a 12-month high of $48.82. The stock has a market cap of $5.32 ... Web14 apr. 2024 · Fidelity Management & Research Co has recently announced that it has increased stake in Ionis Pharmaceuticals Inc. (NASDAQ:IONS) by 0.08%. After grabbing 21.31 million shares, the institutional investor is now in possession of 16360.0 shares of the Healthcare Company.
Ionis analyst coverage
Did you know?
Web9 nov. 2024 · Ionis' revenue was comprised of the following: Total revenue for the three and nine months ended September 30, 2024 increased 20 percent and 18 percent compared … Web12 apr. 2024 · Buy candidate since 2024-04-05 Gain 1.86% PDF. The Ionis Pharmaceuticals stock price gained 1.86% on the last trading day (Thursday, 6th Apr …
WebIONIS PHARMACEUTICALS, INC. : Trading strategies, financial analysis, commentaries and investment guidance for IONIS PHARMACEUTICALS, INC. Stock Berne Stock ... Web6 jan. 2024 · Ionis Pharmaceuticals is currently enrolling patients in the CORE and CORE 2 trials to evaluate the efficacy and safety of olezarsen for patients with sHTG. These studies will provide evidence to establish apoC-III inhibition as an important potential therapeutic modality in reducing excessive TG levels in the blood. 21,22
WebIonis Pharmaceuticals Stock (NASDAQ:IONS), Analyst Ratings, Price Targets, Predictions Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst … Web11 apr. 2024 · Ulz covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Zentalis Pharmaceuticals, and Karyopharm Therapeutics. The word on …
Web13 apr. 2024 · Ionis Pharmaceuticals last announced its quarterly earnings data on February 22nd, 2024. The reported ($0.37) earnings per share (EPS) for the quarter, …
Web29 mrt. 2024 · As the leader in RNA-targeted therapeutics for more than three decades, Ionis has focused every moment on advancing drug discovery, development, and … shane suitsWebDMPK RESEARCH, DEVELOPMENT, OPTION AND LICENSE AGREEMENT . This DMPK RESEARCH, DEVELOPMENT, OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of the 27th day of June, 2012 (the “Effective Date”) by and between ISIS PHARMACEUTICALS, INC., a Delaware corporation, having its principal place of … shane sullivan north sydney councilWeb12 apr. 2024 · One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently... shane summers hickory ncWebThe Ionis antisense pipeline Our antisense technology platform has served as a springboard for drug discovery and realized hope for patients with unmet needs. Our … shane summers mdWeb12 apr. 2024 · The company reported $0.13 EPS for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.01). Certara had a net margin of 4.39% and a return on equity of 5.97%. The business had... shane summers md hickory ncWebBased on 11 analysts offering 12 month price targets for Ionis Pharmaceuticals Inc. Min Forecast. $27.00-27.56%. ... Initiates Coverage On: $31.00-16.82%: 2024-03-21: Mani … shane summersWeb5 apr. 2024 · Benevolent AI made the unusual decision to try inhibiting tropomyosin receptor kinases (Trks), best known for their role in cancer, in atopic dermatitis, and today disclosed a failure. The topical project BEN-2293 was generated by the Benevolent Platform, the group’s AI-enabled drug discovery engine, to block Trks A, B and C. shane sumpter